Share Price and Basic Stock Data
Last Updated: April 3, 2025, 1:41 am
PEG Ratio | 30.03 |
---|
Competitors of Biocon Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Lactose (India) Ltd | 144 Cr. | 102 | 247/84.3 | 20.8 | 36.5 | 0.00 % | 18.0 % | 15.5 % | 10.0 |
MPS Pharmaa Ltd | 5.79 Cr. | 3.03 | 4.33/3.03 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 47.5 Cr. | 64.0 | 94.9/44.5 | 16.1 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 38.1 Cr. | 26.0 | 29.0/8.74 | 38.9 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
Industry Average | 17,746.56 Cr | 1,083.76 | 42.12 | 182.65 | 0.35% | 16.01% | 16.31% | 6.24 |
Quarterly Result
Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,174 | 2,409 | 2,140 | 2,320 | 2,941 | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 |
Expenses | 1,733 | 1,870 | 1,783 | 1,877 | 2,352 | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 |
Operating Profit | 441 | 539 | 356 | 442 | 589 | 957 | 681 | 717 | 903 | 913 | 620 | 685 | 752 |
OPM % | 20% | 22% | 17% | 19% | 20% | 25% | 20% | 21% | 23% | 23% | 18% | 19% | 20% |
Other Income | 48 | 26 | 78 | 48 | -193 | 152 | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 |
Interest | 15 | 10 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 |
Depreciation | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 414 | 407 | 405 | 420 | 425 |
Profit before tax | 269 | 342 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 |
Tax % | 18% | 17% | 15% | 64% | -19% | 17% | 19% | 19% | 7% | 30% | 25% | 72% | 48% |
Net Profit | 220 | 284 | 167 | 82 | -21 | 414 | 149 | 173 | 753 | 223 | 862 | 27 | 81 |
EPS in Rs | 1.56 | 1.99 | 1.20 | 0.39 | -0.35 | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 |
Last Updated: March 3, 2025, 5:13 pm
Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹3,821.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,590.00 Cr. (Sep 2024) to ₹3,821.00 Cr., marking an increase of 231.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹3,070.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,905.00 Cr. (Sep 2024) to ₹3,070.00 Cr., marking an increase of 165.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹752.00 Cr.. The value appears strong and on an upward trend. It has increased from 685.00 Cr. (Sep 2024) to ₹752.00 Cr., marking an increase of 67.00 Cr..
- For OPM %, as of Dec 2024, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 19.00% (Sep 2024) to 20.00%, marking an increase of 1.00%.
- For Other Income, as of Dec 2024, the value is ₹53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Sep 2024) to ₹53.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Dec 2024, the value is ₹223.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 226.00 Cr. (Sep 2024) to ₹223.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹425.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 420.00 Cr. (Sep 2024) to ₹425.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹156.00 Cr.. The value appears strong and on an upward trend. It has increased from 98.00 Cr. (Sep 2024) to ₹156.00 Cr., marking an increase of 58.00 Cr..
- For Tax %, as of Dec 2024, the value is 48.00%. The value appears to be improving (decreasing) as expected. It has decreased from 72.00% (Sep 2024) to 48.00%, marking a decrease of 24.00%.
- For Net Profit, as of Dec 2024, the value is ₹81.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Sep 2024) to ₹81.00 Cr., marking an increase of 54.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.21. The value appears strong and on an upward trend. It has increased from -0.13 (Sep 2024) to 0.21, marking an increase of 0.34.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 4:49 pm
Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,485 | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,300 | 7,143 | 8,184 | 11,174 | 14,756 | 14,762 |
Expenses | 1,942 | 2,190 | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,725 | 5,562 | 6,391 | 8,762 | 11,540 | 11,791 |
Operating Profit | 543 | 687 | 696 | 390 | 980 | 829 | 1,394 | 1,575 | 1,581 | 1,793 | 2,412 | 3,216 | 2,971 |
OPM % | 22% | 24% | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 20% |
Other Income | 255 | 56 | 158 | 639 | 173 | 228 | 340 | 228 | 260 | 72 | 18 | 853 | 1,318 |
Interest | 8 | 2 | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 912 |
Depreciation | 179 | 204 | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,658 |
Profit before tax | 610 | 538 | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,719 |
Tax % | 16% | 20% | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% | 15% | |
Net Profit | 513 | 431 | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,193 |
EPS in Rs | 4.24 | 3.45 | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 6.70 |
Dividend Payout % | 29% | 24% | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% | 6% |
YoY Net Profit Growth
Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | -15.98% | 22.51% | 15.34% | 12.97% | -34.16% | 121.41% | -13.16% | -2.87% | -8.75% | -16.71% | 101.87% |
Change in YoY Net Profit Growth (%) | 0.00% | 38.49% | -7.16% | -2.37% | -47.13% | 155.57% | -134.57% | 10.29% | -5.88% | -7.96% | 118.58% |
Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 22% |
3 Years: | 27% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 6% |
3 Years: | 11% |
TTM: | -31% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 4% |
3 Years: | 0% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 7% |
3 Years: | 6% |
Last Year: | 5% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 15, 2024, 1:35 am
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 100 | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Reserves | 2,595 | 2,927 | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 20,393 |
Borrowings | 267 | 864 | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 16,771 |
Other Liabilities | 1,454 | 1,860 | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 19,364 |
Total Liabilities | 4,416 | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 57,128 |
Fixed Assets | 1,510 | 1,525 | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 34,792 |
CWIP | 312 | 1,206 | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 4,354 |
Investments | 587 | 765 | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,809 |
Other Assets | 2,007 | 2,255 | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,174 |
Total Assets | 4,416 | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 57,128 |
Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹600.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 600.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹20,393.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,183.00 Cr. (Mar 2024) to ₹20,393.00 Cr., marking an increase of 1,210.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹16,771.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 16,277.00 Cr. (Mar 2024) to ₹16,771.00 Cr., marking an increase of 494.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹19,364.00 Cr.. The value appears to be improving (decreasing). It has decreased from 19,693.00 Cr. (Mar 2024) to ₹19,364.00 Cr., marking a decrease of 329.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹57,128.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 55,753.00 Cr. (Mar 2024) to ₹57,128.00 Cr., marking an increase of 1,375.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹34,792.00 Cr.. The value appears strong and on an upward trend. It has increased from 30,644.00 Cr. (Mar 2024) to ₹34,792.00 Cr., marking an increase of 4,148.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹4,354.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,993.00 Cr. (Mar 2024) to ₹4,354.00 Cr., marking a decrease of 3,639.00 Cr..
- For Investments, as of Sep 2024, the value is ₹1,809.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,000.00 Cr. (Mar 2024) to ₹1,809.00 Cr., marking an increase of 809.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹16,174.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,117.00 Cr. (Mar 2024) to ₹16,174.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹57,128.00 Cr.. The value appears strong and on an upward trend. It has increased from 55,753.00 Cr. (Mar 2024) to ₹57,128.00 Cr., marking an increase of 1,375.00 Cr..
Notably, the Reserves (₹20,393.00 Cr.) exceed the Borrowings (16,771.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | 276.00 | -177.00 | 695.00 | 388.00 | 978.00 | 827.00 | -1.00 | -1.00 | -3.00 | -4.00 | -16.00 | -13.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 75 | 76 | 91 | 78 | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 |
Inventory Days | 139 | 116 | 132 | 153 | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 |
Days Payable | 121 | 107 | 125 | 172 | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 |
Cash Conversion Cycle | 93 | 85 | 98 | 59 | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 |
Working Capital Days | 21 | -0 | 12 | 31 | 34 | 18 | 15 | 8 | 80 | 112 | 85 | 2 |
ROCE % | 15% | 15% | 12% | 9% | 12% | 8% | 13% | 12% | 10% | 9% | 6% | 6% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
SBI Contra Fund | 16,770,774 | 1.83 | 463.71 | 10,709,389 | 2025-04-03 | 56.6% |
Mirae Asset Large Cap Fund | 10,709,389 | 0.79 | 296.11 | 10,709,389 | 2025-04-03 | 0% |
SBI Balanced Advantage Fund | 10,021,205 | 0.99 | 277.09 | 10,709,389 | 2025-04-03 | -6.43% |
Quant Flexi Cap Fund | 5,611,098 | 3.73 | 155.15 | 10,709,389 | 2025-04-03 | -47.61% |
Quant Mid Cap Fund | 4,100,000 | 2.09 | 113.37 | 10,709,389 | 2025-04-03 | -61.72% |
Kotak Equity Arbitrage Fund - Regular Plan | 4,025,000 | 0.28 | 111.29 | 10,709,389 | 2025-04-03 | -62.42% |
SBI Arbitrage Opportunities Fund | 3,397,500 | 0.34 | 93.94 | 10,709,389 | 2025-04-03 | -68.28% |
ICICI Prudential India Opportunities Fund | 3,114,146 | 0.5 | 86.11 | 10,709,389 | 2025-04-03 | -70.92% |
Sundaram Mid Cap Fund | 3,080,023 | 0.83 | 85.16 | 10,709,389 | 2025-04-03 | -71.24% |
Sundaram Mid Cap Fund - Institutional Plan | 3,080,023 | 0.83 | 85.16 | 10,709,389 | 2025-04-03 | -71.24% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Basic EPS (Rs.) | 8.55 | 3.88 | 5.44 | 6.24 | 6.32 |
Diluted EPS (Rs.) | 8.54 | 3.87 | 5.42 | 6.19 | 6.30 |
Cash EPS (Rs.) | 24.58 | 16.02 | 14.93 | 13.59 | 11.86 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 210.51 | 187.31 | 78.87 | 70.09 | 61.52 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 210.52 | 187.31 | 78.88 | 70.10 | 61.53 |
Revenue From Operations / Share (Rs.) | 122.90 | 93.07 | 68.17 | 59.22 | 52.50 |
PBDIT / Share (Rs.) | 34.68 | 24.05 | 18.18 | 15.89 | 14.70 |
PBIT / Share (Rs.) | 21.62 | 14.78 | 11.40 | 9.93 | 10.10 |
PBT / Share (Rs.) | 13.40 | 8.86 | 9.91 | 9.56 | 10.12 |
Net Profit / Share (Rs.) | 11.51 | 6.75 | 8.15 | 7.63 | 7.26 |
NP After MI And SOA / Share (Rs.) | 8.52 | 3.85 | 5.40 | 6.17 | 6.24 |
PBDIT Margin (%) | 28.22 | 25.84 | 26.67 | 26.83 | 28.00 |
PBIT Margin (%) | 17.58 | 15.88 | 16.72 | 16.77 | 19.24 |
PBT Margin (%) | 10.90 | 9.52 | 14.54 | 16.14 | 19.28 |
Net Profit Margin (%) | 9.36 | 7.24 | 11.95 | 12.88 | 13.82 |
NP After MI And SOA Margin (%) | 6.92 | 4.14 | 7.92 | 10.42 | 11.87 |
Return on Networth / Equity (%) | 5.16 | 2.58 | 7.69 | 9.83 | 11.15 |
Return on Capital Employeed (%) | 6.37 | 4.07 | 8.26 | 8.32 | 11.61 |
Return On Assets (%) | 1.82 | 0.88 | 3.17 | 3.99 | 5.18 |
Long Term Debt / Equity (X) | 0.65 | 0.85 | 0.47 | 0.39 | 0.18 |
Total Debt / Equity (X) | 0.79 | 0.99 | 0.58 | 0.47 | 0.28 |
Asset Turnover Ratio (%) | 0.27 | 0.30 | 0.12 | 0.17 | 0.19 |
Current Ratio (X) | 0.98 | 1.45 | 2.19 | 1.81 | 1.33 |
Quick Ratio (X) | 0.66 | 0.95 | 1.59 | 1.36 | 0.97 |
Inventory Turnover Ratio (X) | 1.10 | 0.97 | 0.75 | 0.81 | 1.10 |
Dividend Payout Ratio (NP) (%) | 17.61 | 12.96 | 0.00 | 0.00 | 8.42 |
Dividend Payout Ratio (CP) (%) | 6.95 | 3.80 | 0.00 | 0.00 | 4.84 |
Earning Retention Ratio (%) | 82.39 | 87.04 | 0.00 | 0.00 | 91.58 |
Cash Earning Retention Ratio (%) | 93.05 | 96.20 | 0.00 | 0.00 | 95.16 |
Interest Coverage Ratio (X) | 4.27 | 6.89 | 32.29 | 33.05 | 27.19 |
Interest Coverage Ratio (Post Tax) (X) | 2.43 | 3.63 | 17.12 | 16.82 | 13.82 |
Enterprise Value (Cr.) | 50669.85 | 44766.88 | 44360.07 | 51477.10 | 34040.50 |
EV / Net Operating Revenue (X) | 3.43 | 4.01 | 5.42 | 7.24 | 5.40 |
EV / EBITDA (X) | 12.17 | 15.50 | 20.32 | 26.99 | 19.29 |
MarketCap / Net Operating Revenue (X) | 2.15 | 2.22 | 4.91 | 6.90 | 5.15 |
Retention Ratios (%) | 82.38 | 87.03 | 0.00 | 0.00 | 91.57 |
Price / BV (X) | 1.60 | 1.39 | 4.76 | 6.51 | 4.84 |
Price / Net Operating Revenue (X) | 2.15 | 2.22 | 4.91 | 6.90 | 5.15 |
EarningsYield | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 |
After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 8.55. This value is within the healthy range. It has increased from 3.88 (Mar 23) to 8.55, marking an increase of 4.67.
- For Diluted EPS (Rs.), as of Mar 24, the value is 8.54. This value is within the healthy range. It has increased from 3.87 (Mar 23) to 8.54, marking an increase of 4.67.
- For Cash EPS (Rs.), as of Mar 24, the value is 24.58. This value is within the healthy range. It has increased from 16.02 (Mar 23) to 24.58, marking an increase of 8.56.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.51. It has increased from 187.31 (Mar 23) to 210.51, marking an increase of 23.20.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 210.52. It has increased from 187.31 (Mar 23) to 210.52, marking an increase of 23.21.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 122.90. It has increased from 93.07 (Mar 23) to 122.90, marking an increase of 29.83.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 34.68. This value is within the healthy range. It has increased from 24.05 (Mar 23) to 34.68, marking an increase of 10.63.
- For PBIT / Share (Rs.), as of Mar 24, the value is 21.62. This value is within the healthy range. It has increased from 14.78 (Mar 23) to 21.62, marking an increase of 6.84.
- For PBT / Share (Rs.), as of Mar 24, the value is 13.40. This value is within the healthy range. It has increased from 8.86 (Mar 23) to 13.40, marking an increase of 4.54.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 11.51. This value is within the healthy range. It has increased from 6.75 (Mar 23) to 11.51, marking an increase of 4.76.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 8.52. This value is within the healthy range. It has increased from 3.85 (Mar 23) to 8.52, marking an increase of 4.67.
- For PBDIT Margin (%), as of Mar 24, the value is 28.22. This value is within the healthy range. It has increased from 25.84 (Mar 23) to 28.22, marking an increase of 2.38.
- For PBIT Margin (%), as of Mar 24, the value is 17.58. This value is within the healthy range. It has increased from 15.88 (Mar 23) to 17.58, marking an increase of 1.70.
- For PBT Margin (%), as of Mar 24, the value is 10.90. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 10.90, marking an increase of 1.38.
- For Net Profit Margin (%), as of Mar 24, the value is 9.36. This value is within the healthy range. It has increased from 7.24 (Mar 23) to 9.36, marking an increase of 2.12.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 6.92. This value is below the healthy minimum of 8. It has increased from 4.14 (Mar 23) to 6.92, marking an increase of 2.78.
- For Return on Networth / Equity (%), as of Mar 24, the value is 5.16. This value is below the healthy minimum of 15. It has increased from 2.58 (Mar 23) to 5.16, marking an increase of 2.58.
- For Return on Capital Employeed (%), as of Mar 24, the value is 6.37. This value is below the healthy minimum of 10. It has increased from 4.07 (Mar 23) to 6.37, marking an increase of 2.30.
- For Return On Assets (%), as of Mar 24, the value is 1.82. This value is below the healthy minimum of 5. It has increased from 0.88 (Mar 23) to 1.82, marking an increase of 0.94.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.65. This value is within the healthy range. It has decreased from 0.85 (Mar 23) to 0.65, marking a decrease of 0.20.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.79. This value is within the healthy range. It has decreased from 0.99 (Mar 23) to 0.79, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.27. It has decreased from 0.30 (Mar 23) to 0.27, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 24, the value is 0.98. This value is below the healthy minimum of 1.5. It has decreased from 1.45 (Mar 23) to 0.98, marking a decrease of 0.47.
- For Quick Ratio (X), as of Mar 24, the value is 0.66. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 23) to 0.66, marking a decrease of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.10. This value is below the healthy minimum of 4. It has increased from 0.97 (Mar 23) to 1.10, marking an increase of 0.13.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 17.61. This value is below the healthy minimum of 20. It has increased from 12.96 (Mar 23) to 17.61, marking an increase of 4.65.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.95. This value is below the healthy minimum of 20. It has increased from 3.80 (Mar 23) to 6.95, marking an increase of 3.15.
- For Earning Retention Ratio (%), as of Mar 24, the value is 82.39. This value exceeds the healthy maximum of 70. It has decreased from 87.04 (Mar 23) to 82.39, marking a decrease of 4.65.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.05. This value exceeds the healthy maximum of 70. It has decreased from 96.20 (Mar 23) to 93.05, marking a decrease of 3.15.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 4.27. This value is within the healthy range. It has decreased from 6.89 (Mar 23) to 4.27, marking a decrease of 2.62.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.43. This value is below the healthy minimum of 3. It has decreased from 3.63 (Mar 23) to 2.43, marking a decrease of 1.20.
- For Enterprise Value (Cr.), as of Mar 24, the value is 50,669.85. It has increased from 44,766.88 (Mar 23) to 50,669.85, marking an increase of 5,902.97.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.43. This value exceeds the healthy maximum of 3. It has decreased from 4.01 (Mar 23) to 3.43, marking a decrease of 0.58.
- For EV / EBITDA (X), as of Mar 24, the value is 12.17. This value is within the healthy range. It has decreased from 15.50 (Mar 23) to 12.17, marking a decrease of 3.33.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
- For Retention Ratios (%), as of Mar 24, the value is 82.38. This value exceeds the healthy maximum of 70. It has decreased from 87.03 (Mar 23) to 82.38, marking a decrease of 4.65.
- For Price / BV (X), as of Mar 24, the value is 1.60. This value is within the healthy range. It has increased from 1.39 (Mar 23) to 1.60, marking an increase of 0.21.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.15. This value is within the healthy range. It has decreased from 2.22 (Mar 23) to 2.15, marking a decrease of 0.07.
- For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 23) to 0.03, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.37% (Industry Average ROCE: 16.01%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.16% (Industry Average ROE: 16.31%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.66
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.9 (Industry average Stock P/E: 42.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | 20th K.M. Hosur Road, Bengaluru Karnataka 560100 | investor.relations@biocon.com http://www.biocon.com |
Management | |
---|---|
Name | Position Held |
Ms. Kiran Mazumdar Shaw | Executive Chairperson |
Mr. Siddharth Mittal | Managing Director & CEO |
Prof. Ravi Rasendra Mazumdar | Non Exe.Non Ind.Director |
Mr. Eric Vivek Mazumdar | Non Exe.Non Ind.Director |
Mr. Meleveetil Damodaran | Lead Independent Director |
Dr. Vijay Kumar Kuchroo | Independent Director |
Mr. Bobby Kanubhai Parikh | Independent Director |
Mr. Peter John Bains | Independent Director |
Mr. Naina Lal Kidwai | Independent Director |
FAQ
What is the intrinsic value of Biocon Ltd?
Biocon Ltd's intrinsic value (as of 04 April 2025) is ₹367.32 — 7.40% higher the current market price of ₹342.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 41,060 Cr. market cap, FY2025-2026 high/low of ₹405/260, reserves of 20,393 Cr, and liabilities of 57,128 Cr.
What is the Market Cap of Biocon Ltd?
The Market Cap of Biocon Ltd is 41,060 Cr..
What is the current Stock Price of Biocon Ltd as on 04 April 2025?
The current stock price of Biocon Ltd as on 04 April 2025 is 342.
What is the High / Low of Biocon Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biocon Ltd stocks is ₹405/260.
What is the Stock P/E of Biocon Ltd?
The Stock P/E of Biocon Ltd is 49.9.
What is the Book Value of Biocon Ltd?
The Book Value of Biocon Ltd is 175.
What is the Dividend Yield of Biocon Ltd?
The Dividend Yield of Biocon Ltd is 0.15 %.
What is the ROCE of Biocon Ltd?
The ROCE of Biocon Ltd is 5.96 %.
What is the ROE of Biocon Ltd?
The ROE of Biocon Ltd is 5.25 %.
What is the Face Value of Biocon Ltd?
The Face Value of Biocon Ltd is 5.00.